Strategic partnerships Jellatech has already engaged in a notable partnership with Hugel to develop and commercialize cell-based human collagen for medical aesthetics, signaling a clear opportunity to pursue co-development or distribution deals with additional medical aesthetics players, dermatology clinics, and regenerative medicine suppliers.

High TAM upside The potential market for human collagen is implied to be substantially larger than traditional animal-derived markets, suggesting a strong sales case to target biopharma, regenerative medicine, and cosmeceutical segments seeking human-identical proteins with superior performance and consistency.

North Carolina footprint Recent facility expansions in North Carolina demonstrate capacity growth and local scale-up potential; BD opportunities exist with nearby universities, contract manufacturers, contract research organizations, and healthcare clusters to shorten time-to-market for collagen-based products.

Cell culture advantage Jellatech’s proprietary human cell-based production enables reliable, fully functional human type I collagen, offering a competitive differentiator for customers requiring high-purity, bio-identical proteins in tissue engineering, aesthetics, and therapeutic applications.

Cross-sector demand Beyond healthcare, the company’s animal-free collagen and proteins align with food, cosmetics, and pet wellness markets; this presents cross-sell and channel expansion opportunities with cosmetic brands, nutraceuticals, and pet-food manufacturers seeking ethical, scalable proteins.